Crossmark

Complement in disease: a defence system turning offensive

Crossref DOI link: https://doi.org/10.1038/nrneph.2016.70

Published Online: 2016-05-23

Published Print: 2016-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ricklin, Daniel

Reis, Edimara S.

Lambris, John D.
License Information

Text and Data Mining valid from 2016-05-23
More Information

Article History

First Online: 23 May 2016

Competing interests

: J.D.L and D.R. are inventors of patents or patent applications that describe the use of complement inhibitors for therapeutic purposes. J.D.L. is the founder of Amyndas Pharmaceuticals, which is developing complement inhibitors. E.S.R. declares no competing interests.